Recent research suggests that levels of phosphorylated neurofilament heavy chain (pNF-H) could serve as a response biomarker in SMA individuals undergoing Nusinersen treatment (11–13). The gene discussed is NEFH; the disease is proximal spinal muscular atrophy.